GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a dual NADPH oxidase Nox1/Nox4 inhibitor with nanomolar potency (Ki: 140 nM for Nox1, 110 nM for Nox4) that suppresses ROS production and downstream signaling such as Akt/mTOR and NF-κB in vitro and in vivo (Yang et al., 2025). It lowers hypoxia-induced H₂O₂ release, inhibits proliferation of human pulmonary vascular cells, and modulates TGF-β1 and PPARγ expression. Oral GKT137831 (30–60 mg/kg/day) attenuates pulmonary vascular remodeling, liver fibrosis, and diabetes-accelerated atherosclerosis in mouse models. The product is provided by APExBIO and is optimized for redox biology workflows at concentrations between 0.1–20 μM for 24-hour incubations. Clinical studies support its translational potential in oxidative stress-driven pathologies (APExBIO Product Page).

Biological Rationale

NADPH oxidases (Nox) are membrane-bound enzyme complexes generating reactive oxygen species (ROS), which serve as signaling molecules but also contribute to pathological processes when dysregulated. Nox1 and Nox4 are two critical isoforms implicated in vascular remodeling, fibrosis, and metabolic dysfunction (Yang et al., 2025). Excess ROS can drive redox imbalance, activate pro-inflammatory signaling (e.g., NF-κB), and induce cellular injury. Targeted inhibition of Nox1/Nox4 reduces ROS-mediated damage, providing a rational therapeutic approach for diseases where oxidative stress is central (see GKT137831: Advanced Dual Nox1/Nox4 Inhibitor for Pathological Redox Biology—this article details translational connections to lipid scrambling and immune modulation, which are further clarified here with new clinical data).

Mechanism of Action of GKT137831

GKT137831 binds selectively to Nox1 and Nox4, inhibiting their catalytic activity with Ki values of 140 nM and 110 nM, respectively (APExBIO). This action dramatically reduces intracellular and extracellular ROS, notably hydrogen peroxide (H₂O₂). By lowering ROS, GKT137831 disrupts redox-sensitive signaling cascades:

• Akt/mTOR pathway: Suppressed, leading to reduced cell proliferation and growth.
• NF-κB pathway: Inhibited, decreasing pro-inflammatory gene expression.
• TGF-β1 and PPARγ modulation: Downregulation of TGF-β1 and upregulation of PPARγ, mitigating fibrotic responses.

In vitro, GKT137831 diminishes H₂O₂ release under hypoxic conditions and blocks proliferation of human pulmonary artery endothelial and smooth muscle cells. In vivo, it prevents pathological remodeling in pulmonary, hepatic, and vascular tissues without affecting unrelated redox systems (see also: GKT137831 and Redox–Ferroptosis Crosstalk—this article updates the mechanistic integration with new benchmarks).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 (Ki = 140 nM) and Nox4 (Ki = 110 nM) enzymatic activity in cell-free assays at 25°C, pH 7.4 (APExBIO, Product Page).
• Reduces hypoxia-induced H₂O₂ release in human pulmonary artery endothelial cells (HPAECs) with 1–10 μM for 24 h (Yang et al., 2025, DOI).
• Attenuates proliferation of HPAECs and human pulmonary artery smooth muscle cells (HPASMCs) at 1–10 μM, measured by BrdU incorporation.
• Oral GKT137831 (30–60 mg/kg/day) for 21–28 days reduces chronic hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in C57BL/6 mice (Yang et al., 2025, DOI).
• Suppresses liver fibrosis in murine CCl₄-induced model, with decreased TGF-β1 expression (measured by qPCR, ELISA).
• Attenuates diabetes-accelerated atherosclerosis in ApoE^−/− mice at 60 mg/kg/day (APExBIO, Product Page).
• Soluble at ≥39.5 mg/mL in DMSO at room temperature, but insoluble in water; store at −20°C, avoid long-term solution storage (APExBIO).

Applications, Limits & Misconceptions

Applications:

• Oxidative stress research in fibrosis, vascular remodeling, and metabolic disease models.
• Dissection of redox-driven signaling pathways (Akt/mTOR, NF-κB, TGF-β1, PPARγ).
• Pharmacological benchmarking for dual Nox1/Nox4 inhibition versus pan-Nox or antioxidant agents.
• Preclinical testing in murine models of pulmonary hypertension, liver fibrosis, and atherosclerosis.

For deeper workflow and protocol comparisons, see GKT137831: Precision Dual Nox1/Nox4 Inhibition for Reliable Redox Biology, which offers practical laboratory guidance—this article extends those insights with mechanistic and translational updates.

Common Pitfalls or Misconceptions

• GKT137831 does not inhibit Nox2 or other ROS sources (e.g., xanthine oxidase, mitochondrial ETC); its selectivity is restricted to Nox1 and Nox4 (APExBIO).
• It is insoluble in water; improper dissolution can lead to inaccurate dosing or precipitation artifacts.
• Long-term storage of solutions at room temperature or above −20°C degrades compound efficacy; always prepare fresh aliquots for experiments.
• Observed effects in non-mammalian or non-redox-centric models may not translate, as GKT137831's action is context-dependent.
• Clinical efficacy is emerging but not yet established for all oxidative stress diseases; preclinical data should not be over-extrapolated.

Workflow Integration & Parameters

GKT137831 is typically used in vitro at 0.1–20 μM for ~24 h incubations. For in vivo mouse studies, oral dosing is 30–60 mg/kg/day for 2–4 weeks. Compound solubility is ≥39.5 mg/mL in DMSO; for ethanol, ≥2.96 mg/mL with warming and sonication. APExBIO recommends storage at −20°C and avoiding repeated freeze-thaw cycles. Standard controls include vehicle (DMSO) and non-Nox-targeted ROS inhibitors for benchmarking. For further details on advanced workflow integration, see GKT137831: Selective Nox1/Nox4 Inhibitor for Oxidative Stress Applications. This article updates the use cases with new clinical trial data and solution handling parameters.

Conclusion & Outlook

GKT137831 (SKU B4763, APExBIO) provides robust, selective inhibition of Nox1/Nox4-driven ROS production. Its validated biochemical and pharmacological profile supports its use in oxidative stress, fibrosis, and vascular remodeling research. Ongoing clinical studies will further define its therapeutic scope. For full product details and ordering, visit the GKT137831 product page.